- £35.85bn
- £44.28bn
- £11.30bn
- 82
- 25
- 95
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8,480 | 9,892 | 9,545 | 10,858 | 11,302 |
Cost of Revenue | |||||
Gross Profit | 5,231 | 6,098 | 5,984 | 6,725 | 6,962 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,580 | 8,265 | 7,872 | 9,241 | 9,195 |
Operating Profit | 900 | 1,627 | 1,673 | 1,617 | 2,107 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 886 | 1,591 | 1,636 | 1,618 | 1,628 |
Provision for Income Taxes | |||||
Net Income After Taxes | 687 | 1,181 | 1,439 | 1,119 | 1,111 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 655 | 1,145 | 1,390 | 1,060 | 1,049 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 655 | 1,145 | 1,390 | 1,060 | 1,049 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.13 | 0.174 | 0.198 | 0.176 | 0.144 |
Dividends per Share |